

Journal of Visualized Experiments

Method to Assess Monocyte Chemotactic Activity in vivo and Characterize the Macrophage Phenotype Blood Monocytes are Poised to Differentiate into. --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59706R1
Full Title:	Method to Assess Monocyte Chemotactic Activity in vivo and Characterize the Macrophage Phenotype Blood Monocytes are Poised to Differentiate into.
Keywords:	monocytes macrophages chemotaxis inflammation monocyte priming Matrigel
Corresponding Author:	Reto Asmis Wake Forest University School of Medicine Winston-Salem, NC UNITED STATES
Corresponding Author's Institution:	Wake Forest University School of Medicine
Corresponding Author E-Mail:	rasmis@wakehealth.edu
Order of Authors:	Yong Joo Ahn Luxi Wang Reto Asmis
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Winston-Salem, NC



CENTER FOR PRECISION MEDICINE

Reto Asmis, PhD
Professor, Department of Medicine
Associate Director for Education, Center for Precision Medicine
rasmis@wakehealth.edu

Dear Dr. Upponi

Attached please find our revised manuscript entitled ***A Novel Method to Assess Monocyte Chemotactic Activity in vivo***. The material has not been previously published and it is not under consideration elsewhere. We have now generated new data, addressed all editorial and reviewers' concerns, and changed the manuscript accordingly.

All authors have read the revised manuscript, take responsibility for its content and have agreed to this submission. I have disclosed my conflict of interest in the manuscript. The other authors have no conflicts of interest to declare.

Sincerely,

Reto

Reto Asmis, Ph.D.
Professor, Internal Medicine, Section on Molecular Medicine
Associate Director for Education, Center for Precision Medicine
Wake Forest School of Medicine

TITLE:

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages

AUTHORS & AFFILIATIONS:

Yong Joo Ahn¹, Luxi Wang¹, Reto Asmis^{1,2}

¹Department of Internal Medicine, Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

²Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA

Corresponding Author:

Reto Asmis (rasmis@wakehealth.edu)

Email Addresses of Co-Authors:

Yong Joo Ahn (yahn@wakehealth.edu)

Luxi Wang (luxwang@wakehealth.edu)

KEYWORDS:

Matrigel, MCP-1, Monocyte, Macrophage, Single-Cell Western blot, Mouse Models, Atherosclerosis

SHORT ABSTRACT:

Here we present a protocol to quantify the chemotactic activity of blood monocytes in mouse models, to assess the effects of nutritional, pharmacological and genetic interventions on blood monocyte and to characterize the blood monocytes derived macrophages in mouse models using monocyte-chemoattractant protein-1 (MCP-1)-loaded basement membrane-derived gel plugs.

LONG ABSTRACT:

Tissue homeostasis and repair are critically dependent on the recruitment of monocyte-derived macrophages. Both under- and over-recruitment of monocyte-derived macrophages can impair wound healing. We showed that high fat and high sugar diets promote monocyte priming and dysfunction, converting healthy blood monocytes into a hyper chemotactic phenotype poised to differentiate into macrophages with dysregulated activation profiles and impaired phenotypic plasticity. The over-recruitment of monocyte-derived macrophages and recruitment of macrophages with dysregulated activation profiles is believed to be a major contributor to the development of chronic inflammatory diseases associated with metabolic disorders, including atherosclerosis and obesity. The goal of this protocol is to quantify the chemotactic activity of blood monocytes as a biomarker for monocyte priming and dysfunction and to characterize the macrophage phenotype blood monocytes are poised to differentiate into in these mouse models. Using single cell Western blot analysis, we show that after 24 h 33% of cells recruited into MCP-1-loaded basement membrane-derived gel plugs injected into mice are monocytes and macrophages; 58% after day 3. However, on day 5, monocyte and macrophage numbers were significantly decreased. Finally, we show that this assays also allows for the isolation of live

macrophages from the surgically retrieved basement membrane-derived gel plugs, which can then be subjected to subsequent characterization by single cell Western blot analysis.

INTRODUCTION:

The recruitment of monocyte-derived macrophages is essential for the development of chronic inflammatory diseases associated with metabolic disorders, including atherosclerosis and obesity¹⁻⁴. The number of monocyte-derived macrophages at sites of tissue injury as well as their plasticity are critical for the tissue homeostasis and repair. Both under- and over-recruitment of monocyte-derived macrophages can impair wound healing⁵. Triggering local tissue inflammation, for example, by the accumulation and oxidation of low-density lipoprotein (LDL) in the aortic wall or inflammatory activation of adipocytes by fatty acids or bacterial lipopolysaccharide leaking through the intestinal barrier, leads to the release of inflammatory mediators, including chemokines such as monocyte chemoattractant protein-1 (MCP-1/CCL2). MCP-1 is a member of the C-C chemokine family and a key chemoattractant responsible for the recruitment of monocyte-derived macrophages to sites of tissue inflammation and injury⁶⁻¹⁰. Inflammatory activation of vascular endothelium results in the expression of adhesions molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)^{11,12}, allowing circulating monocytes activated by MCP-1 to roll along, firmly adhere to and subsequently transmigrate into the subendothelial space¹². Infiltrating monocytes differentiate into macrophages, which can be activated into a proinflammatory phenotype, driving the acute inflammatory process. Driven by the microenvironment, pro-inflammatory macrophages can convert into inflammation-resolving macrophages, which play critical roles in the clearing of inflammatory cells, removing pro-inflammatory signals and completing tissue repair and wound healing^{12,13}.

Chronic metabolic stress primes monocytes for dramatically enhanced responsiveness to chemoattractants and increased monocyte recruitment, and we showed that primed monocytes give rise to macrophages with dysregulated activation programs and polarization states¹⁴⁻¹⁶. Monocyte priming promotes atherosclerosis, obesity, and possibly other chronic inflammatory diseases associated with metabolic disorders such as steatohepatitis, kidney diseases and possibly cancer. To assess and quantify monocyte priming in mouse models of human diseases, we developed a new technique to assess the priming state of blood monocytes by measuring the chemotactic activity in vivo¹⁴⁻¹⁷. Our approach involves the injection of basement membrane-derived gel loaded with either a chemoattractant – we commonly use MCP-1 – or vehicle into the left and right flank, respectively, of mice. When carefully injected subcutaneously, the basement membrane-derived gel will form a single plug, from which the chemokines can diffuse and create a defined chemotactic gradient that is not affected by the metabolic or inflammatory state of the surrounding tissue or the recipient mouse.

The basement membrane-derived gel we use for our assay is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in such extracellular matrix (ECM) proteins. This complex protein mixture contains laminin (60%), collagen IV (30%), the bridging molecule entactin (8%), and a number of growth factors. The basement membrane matrix plug assay was originally developed to investigate angiogenesis in

response to various growth factors^{18,19}. However, in order to study monocyte chemotaxis, it is important to use growth factor-depleted basement membrane-derived gel to minimize endothelial cell recruitment and angiogenesis. What makes Matrigel (referred to as basement membrane-derived gel henceforth) unique and particularly useful is that at temperatures below 10 °C it liquefies, allowing for chemokines to be dissolved. At temperatures above 22 °C, the basement membrane-derived solution rapidly undergoes a phase transition and rapidly forms a hydrogel. The plugs can be surgically excised, cleaned and dissolved with a bacillus-derived neutral metalloprotease to yield single cell suspensions, which can be analyzed on a fluorescence-activated cell sorter (FACS), by RNAseq, single-cell RNA and a variety of other omics techniques. Here we describe the use of single-cell Western blot analysis for the characterization of the cell populations recruited into the basement membrane-derived gel plugs one, three or five days after injection.

PROTOCOL:

All the methods described in this protocol have been approved by the Institutional Animal Care and Use Committee at Wake Forest School of Medicine.

1. Preparation of MCP-1-loaded growth factor-reduced basement membrane-derived solution

NOTE: This is a sterile procedure.

1.1 Clean cell culture hood with disinfectant before preparing the basement membrane derived solution (e.g., Matrigel).

1.2 Prepare individually packed sterile 1 mL syringe and wipe the top of the basement membrane derived solution vial with an alcohol swab before loading it into the syringe.

1.3 Completely thaw the growth factor-reduced basement membrane-derived solution on ice.

CAUTION: If the basement membrane matrix is thawed at room temperature (RT), ensure a small ice particle remains to prevent the solution from gelling.

1.4 Once thawed, open the vial and mix MCP-1 or 1xPBS with 0.1% BSA in the cell culture hood.

1.5 Prepare a 1 mL of the sterile syringe with a 26G needle and cool on ice.

1.6 Prepare a stock solution of MCP-1 by dissolving MCP-1 to a final concentration of 50 µg/mL in 1x PBS with 0.1% BSA.

1.7 Dilute MCP-1 in 5 mL cold basement membrane-derived solution to a final concentration of 500 ng/mL. Prepare an equal amount of basement membrane-derived solution with vehicle only (1x PBS contain 0.1% BSA).

1.8 Load 500 μ L of basement membrane-derived solution (with or without MCP-1) in the cold 1 mL syringe.

1.9 Remove all air bubbles from the basement membrane-derived solution-loaded syringe before making the injection to ensure a uniform plug formation.

2. Injection of basement membrane-derived solution

2.1 Spray 70% ethanol around the procedure area before and during the procedure to keep the environment sterile.

2.2 To induce anesthesia, place the mouse in an anesthesia chamber and adjust the vaporizer to 2% isoflurane.

2.3 Monitor the depth of anesthesia by monitoring the respiratory rate (rate/min), corneal reflex and movement of whiskers.

2.4 During the whole procedure, maintain anesthesia using a nose cone.

2.5 During the procedure keep monitoring the respiratory rate (rate/min), corneal reflex and movement of whiskers to verify the depth of anesthesia.

2.6 After the mouse is fully anesthetized, slowly inject (approximately 100 μ L/s) the basement membrane-derived solution subcutaneously into the right (no MCP-1) and left (with MCP-1) flank of the mouse, respectively. If the injection is too slow, the basement membrane-derived gel plugs can become irregularly shaped, or even fragmented, and difficult to remove.

2.7 Hold the syringe for 20-30 s after the injection to prevent the leakage of the solution and to allow a single smooth gel-plug to form.

2.8 Carefully observe the mouse during recovery from anesthesia.

2.9 Return the mouse to the original cage once the mouse starts moving around in the cage.

3. Harvest the basement membrane-derived gel plugs

3.1 Weigh two separate 1.5 mL microcentrifuge tubes for each mouse and label them.

3.2 Three days after injection of the basement membrane-derived solution, euthanize the mouse in the anesthetic chamber using 3% isoflurane followed by cervical dislocation.

3.3 Remove the mouse's dorsal fur using hair clippers or apply hair remover cream with cotton-tipped sticks for 5 min and then wipe off.

3.4 Hold the mouse skin using forceps around the lower thoracic and upper lumbar vertebra and make a 2 mm-long incision into the skin.

3.5 Cut the midline of the back of the mouse from an incision made up to cervical vertebrae and down to 1 cm above caudal vertebra junction (tail junction) using surgical scissors.

3.6 Separate the skin from the muscle layer and pin-down the skin on a polystyrene foam platform.

3.7 Carefully hold the fibrous capsule that contains the basement membrane-derived gel plug using fine forceps and remove the fibrous capsule using fine scissors to clean the plug.

3.8 Remove the cleaned basement membrane-derived gel plug and transfer to 1.5 mL microcentrifuge (see 3.1).

3.9 Weigh the microcentrifuge tube with the cleaned basement membrane-derived gel plug and calculate the weight of the basement membrane-derived gel plug.

4. Digest the basement membrane-derived gel plugs

4.1 Thaw dispase (10 mL) on the ice.

4.2 Mince the basement membrane-derived gel plug in the microcentrifuge tube using clean fine scissors.

4.3 Add 800 μ L of dispase into each microcentrifuge tube containing basement membrane-derived gel plug.

4.4 Vortex with maximum speed for 10 s to disrupt the plug.

4.5 Incubate the microcentrifuge tubes for 2 h at 37 °C at 1400 rpm in a thermomixer to completely dissolve the basement membrane-derived gel plug.

4.6 After 2 h, centrifuge at 400 x *g* for 10 min at RT. Carefully remove and discard the supernatant.

4.7 Resuspend the pellet in 1 mL of 1x PBS by inverting or tapping.

4.8 Repeat the centrifugation at 200 x *g* for 10 min at RT. Carefully remove and discard the supernatant.

4.9 Resuspend the pellet in 300 μ L of PBS.

4.10 Take 50 μ L of cell suspension in a separate microcentrifuge tube.

4.11 Add 0.5 μ L of calcein AM (1 M) to the cell suspension.

NOTE: Calcein AM is a green fluorescent cell viability dye which only accumulates in living cells.

4.12 Incubate the cells in a CO₂ incubator at 37 °C for 10 min.

4.13 Count green fluorescent (live) and non-fluorescent (dead) cells using an automated cell counter.

5. Determining cell composition in the cell suspension using single-cell Western blot (scWB) analysis

5.1 Rehydrate the scWB chip before use in 15 mL of 1x suspension buffer in a Petri dish for at least 10 min at RT.

5.2 Add 1 mL of the diluted single cell suspension (10,000 - 100,000 cells/mL) to the rehydrated chip. Set the surface onto the bottom of a 10 cm Petri dish. Ensure that the surface is set flat.

5.3 Cover the Petri dish with a lid to prevent drying and let the cells settle for 5-15 min by gradient.

5.4 Place the chip under a bright-field microscope and inspect the wells at 10x magnification.

NOTE: Approximately 15-20% microwells should be occupied by a single-cell, fewer than 2% of wells should contain 2 or more cells

5.5 Tilt the 10 cm Petri dish containing the chip by 45 degrees.

5.6 Wash the chip with the 1x suspension buffer to remove uncaptured cells from the surface of the chip by gentle pipetting from top to bottom of the chip. Repeat 3 times.

5.7 Prepare the single cell Western instrument.

5.8 Set the lysis time, electrophoresis time, and UV capture time. To analyze recruited macrophages recovered from the basement membrane-derived gel plug, use the following settings: lysis time: 0 s; electrophoresis time: 160 s; UV capture time 240 s.

5.9 Carefully load the chip into the electrophoresis cell of single cell Western instrument, gel-side facing. Use caution not to damage the gel side of the chip.

5.10 Pour the lysis/running buffer into the chamber and completely cover the entire single cell Western chip. Start the cell lysis.

5.11 Run scWB instrument using the setting listed in 5.8.

5.12 Once the run is complete, transfer the chip to a 10 cm Petri dish and wash the chip twice with 1x washing buffer for 10 min at RT.

5.13 Prepare dilutions of primary antibody (anti-vinculin: 1:10; anti-CD45: 1:15, anti-CD11b: 1:20, anti-F4/80: 1:10) in a total volume of 80 μ L of antibody diluent (mix 8 μ L of antibody 1 plus 8 μ L of antibody 2 plus 64 μ L of diluent).

5.14 Add 80 μ L of the primary antibody solution to the antibody probing chamber and lower the chip gel-side down so that the antibody solution wicks across the chip.

5.15 Incubate with the primary antibody solution for 2 h at RT.

5.16 Wash the chip three times for 10 min in 1x washing buffer on the shaker.

5.17 Wash the chip once for 10 min in the water on the shaker to desalt the gel.

5.18 Prepare a 1:20 dilution of secondary antibody in a total volume of 80 μ L (mix 2 μ L of secondary antibody plus 78 μ L of diluent).

5.19 Incubate the chip with secondary antibody for 1 h at RT protected from light.

5.20 Wash the chip three times for 10 min with 1x washing buffer on the shaker.

5.21 Spin the chip using a slide spinner to remove any remaining washing buffer.

5.22 Scan the chip on a dual-laser microarray scanner at 5 μ m resolution at the spectral channel of the fluorophore coupled to the secondary antibodies.

5.23 Analyze data using scWB-specific software.

6. Stripping the scWB chip

6.1 Store the scanned chip in wash buffer until ready to strip.

6.2 Place the water bath in a fume hood.

6.3 Place a 50 mL tube rack in the water bath with the water just 1 cm above the rack and set the water temperature at 60 $^{\circ}$ C.

6.4 Prepare the stripping buffer. For 1L of stripping buffer solution, dissolve 9.85 g of Tris-HCl (pH 6.8) and 20 g of SDS in 900 mL of distilled water and adjust pH. Then fill with distilled water to 1L. Add 0.8% (v/v) of β -mercaptoethanol (β -ME; 14.3 M) immediately before each use.

6.5 After the initial scan, place the chip in a 10 cm Petri dish before stripping.

6.6 For each chip, take 40 mL of stripping buffer and add 320 μ L of β -ME.

CAUTION: β -ME is toxic and hazardous to human and environment. The following procedure should be done in a fume hood.

6.7 Place the chip in the canister and seal the canister with parafilm to prevent water leaking into the canister.

6.8 Place the canister inside the tube rack in the pre-warmed water bath.

6.9 Incubate for 90 min.

6.10 Carefully remove the chip from the canister and place in a fresh Petri dish.

6.11 Briefly wash the chip once with 1x wash buffer. Then add 15 mL of 1x washing buffer to the Petri dish.

6.12 Wash the chip for 15 min on a shaker. Repeat the wash step four times.

NOTE: Chip is ready for the next primary antibody (see steps 5.12 – 5.21).

REPRESENTATIVE RESULTS:

To access the responsiveness of blood monocytes to chemoattractants, we injected vehicle-loaded and MCP-1 loaded basement membrane-derived solution into the left and right flanks of each mouse. Basement membrane-derived gel plugs were removed 1, 3 and 5 days after injections, dissolved and cells recruited into each plug were counted (**Figure 1A**). By subtracting the cell count in the vehicle-loaded plug (open bars) from the cell count in the MCP-1 loaded plug (closed bars), we obtained the number of cells specifically recruited in response to MCP-1 (Δ Cell Number, **Figure 1B**). We observed an accelerated MCP-1-specific recruitment and accumulation of cells over the 5-day period, with rates increasing from 31,000 cells/day (Day 1) to 78,000 cells/day (Day 3) and 136,000 cells/day at day 5 (**Figure 1B**).

To identify the cell types that entered the basement membrane-derived gel plugs, we subjected the cells isolated from each plug to single cell Western blot analysis (scWB), probing for CD45, CD11b and F4/80 expression to identify monocytes (CD11b⁺F4/80⁻), macrophages (CD11b⁺F4/80⁺ plus CD11b⁻F4/80⁺) and remaining non-monocytic leukocytes (CD45⁺CD11b⁻F4/80⁻) (**Figure 2**). The scWB chips were then probed for vinculin to determine the total cell numbers on each gel and to confirm single cell occupancy of the microwells on the scWB chip. The percentage of monocytes within the MCP-1-loaded basement membrane-derived gel plugs was low at day 1, 20%, peaked at day 3 at 47%, respectively before dropping to 14% at day 5 (**Figure 2D**). Macrophage numbers within the MCP-1-loaded basement membrane-derived gel plugs increased steadily from 13% at day 1, to 22% on day 3 and 23% on day 5. For MCP-1-loaded plugs,

the percentage of monocytes plus macrophages within the isolated cell population was highest at day 3, 31% in vehicle loaded plugs (**Figure 3A**) and 58% in MCP-1-loaded plugs (**Figure 3B**), indicating that after 3 days the vast majority of cells recruited by MCP-1–dependent chemotaxis are monocytes and macrophages. Even though the total number of monocytes plus macrophages was higher at day 5 compared to day 3 (**Figure 3C and D**), due to the significantly higher proportion of monocytes and macrophages in the total cell population (**Figure 3A and B**), the cell count at day 3 more accurately reflects blood monocyte chemotaxis and recruitment. We, therefore, routinely inject the basement membrane-derived solution three days prior to sacrificing the animals. Whether all macrophages recruited by MCP-1 are monocyte-derived or resident macrophages recruited from neighboring tissues contributed was not determined.

Statistical analysis of the data shown here was conducted with analysis software (e.g., SigmaPlot 14). ANOVA followed by the Fischer LSD test was used to compare mean values between experimental groups. All data are presented as mean \pm SD of at least 3 independent experiments. Results were considered statistically significant at the $P < 0.05$ level.

FIGURE AND TABLE LEGENDS:

Figure 1: Quantitation of cells recruited into subcutaneous basement membrane-derived gel plugs. (A) Absolute cell numbers for vehicle-loaded (open bars) and MCP-1-loaded basement membrane-derived gel plugs (closed bars). (B) The number of cells recruited into basement membrane-derived gel plugs by MCP-1 calculated as the difference in cell numbers between MCP-1-loaded and vehicle-loaded plugs. Results are shown as mean \pm SD (n=4)

Figure 2: Analysis of cell populations recruited into basement membrane-derived gel plugs by single cell western blot analysis. (A+B) Representative examples are shown for the scWB analysis of a vehicle-loaded (**Control**) and an MCP-1-loaded plug (**MCP-1**) isolated from a mouse three days after injection. Chips labeled with antibodies directed against CD45, CD11b and F4/80 followed by fluorescent secondary antibodies as described in the Protocol. The fluorescence intensity of the labeled band for each individual cell is shown as peak area. (C+D) Cell populations were identified as monocytes (CD11b⁺F4/80⁻, ●), macrophages (CD11b⁺F4/80⁺ plus CD11b⁻F4/80⁺, ●) or as non-monocytic leukocytes (CD45⁺, ●). The remaining cells were labeled “other” (●). Results are shown as mean \pm SD (n = 3).

Figure 3: Monocyte and macrophage content of basement membrane-derived gel plugs. Quantitative analysis of recruited monocyte and macrophage content in vehicle-loaded and MCP-1-loaded plugs removed at day 1, 3 and 5 post-injection. Values are shown as percent of the total cell population (**A + B**) and in absolute cell numbers per plug (**C + D**). Results are shown as mean \pm SD (n = 3).

DISCUSSION:

We developed an in vivo chemotaxis assay, making use of the unique physical properties of the basement membrane-derived matrix and the ability to load this unique matrix with chemokines and inject it into mice. The assay allows us to assess in living mice the responsiveness of monocytes (and macrophages) to chemokines, as illustrated here for MCP-1, and the effects of

either genetic manipulation or pharmacological, dietary and other environmental exposures on monocyte chemotaxis. Because the chemokine gradient we create in these mice is essentially unaffected by genetic, pharmacological, dietary or environmental exposure, changes in monocyte chemotactic activity actually reflect functional changes in these monocytes and, as we showed previously, also the reprogramming at both the protein and transcriptional level^{17,20}. We reported that metabolic stress in mice increases monocyte responsiveness to chemoattractant and that this hyper-chemotactic activity correlates with increased protein S-glutathionylation, a reversible, redox-dependent posttranslational protein modification, which in most cases leads to loss of enzymatic and protein function^{21,22}, and in some instances even promotes protein degradation^{16,23}.

To successfully execute this procedure and to obtain optimal results with this assay it is critical that accurate volumes of basement membrane-derived solution are injected slowly to create a singular well-formed plug and fibrous capsules should be removed completely to get clean plugs when harvest basement membrane-derived gel plugs, facilitates the dissolution of the entire plug in the disperse solution. Our data show that leaving the plug in the animals for three days optimizes 1) the signal intensity, i.e., the number of monocytes and macrophages recruited into each plug, 2) the selectivity of the signal, i.e., the content of monocytes and macrophages within the total cell populations and 3) the specificity of the signal, i.e. the increase in monocytes and macrophages in response to MCP-1 compared to vehicle. Finally, we demonstrate how state-of-the-art single cell-based approaches in conjunction with the basement membrane-derived gel plug assay can be used to characterize the monocytes recruited into the plugs and thus obtain a snapshot of the potential phenotype of the monocyte-derived macrophages being recruited to sites of injury in any given mouse model in response to specific genetic, pharmacological, dietary or environmental interventions.

There are a number of limitations of the assay to be considered. First, mouse handling, including anesthesia, injection of basement membrane-derived solution, and surgical dissection requires practice to generate single plugs and reproducible data. Second, while most cells recruited into the MCP-1 loaded plugs are monocytes and macrophages, a substantial number are not. This may affect the interpretation of other, non-single-cell based analytical assays performed on this cell population. Finally, since the cell lysis conditions for scWB are mild, migration distances of proteins may differ from standard WB and may not correlate with protein size. Therefore, both cell lysis and run times have to be validated for each new protein to be tested and each primary antibody used.

ACKNOWLEDGMENTS:

This project was supported by grants to R.A. from the NIH (AT006885).

DISCLOSURES:

None.

REFERENCES

- 1 Moore, K. J., Tabas, I. Macrophages in the pathogenesis of atherosclerosis. *Cell*. **145** (3),

341-355, (2011).

2 Chawla, A., Nguyen, K. D., Goh, Y. P. Macrophage-mediated inflammation in metabolic disease. *Nature Reviews Immunology*. **11** (11), 738-749, (2011).

3 McNelis, J. C., Olefsky, J. M. Macrophages, immunity, and metabolic disease. *Immunity*. **41** (1), 36-48, (2014).

4 Akiyama, T. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. *Journal of Biological Chemistry*. **262** (12), 5592-5595, (1987).

5 Nahrendorf, M., Pittet, M. J., Swirski, F. K. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. *Circulation*. **121** (22), 2437-2445, (2010).

6 Gosling, J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. *Journal of Clinical Investigation*. **103** (6), 773-778, (1999).

7 Fantuzzi, L. et al. Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. *Blood*. **94** (3), 875-883, (1999).

8 Boring, L., Gosling, J., Cleary, M., Charo, I. F. Decreased lesion formation in CCR2^{-/-} mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature*. **394** (6696), 894-897, (1998).

9 Han, K. H., Tangirala, R. K., Green, S. R., Quehenberger, O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. *Arteriosclerosis Thrombosis Vascular Biology*. **18** (12), 1983-1991, (1998).

10 Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *Journal of Clinical Investigation*. **116** (6), 1494-1505, (2006).

11 Davies, M. J. et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. *Journal of Pathology* **171** 223-229, (1993).

12 Anderson, T. J. et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion (see comments). *New England Journal of Medicine*. **332** (8), 488-493, (1995).

13 Herold, S., Mayer, K., Lohmeyer, J. Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair. *Frontiers in Immunology*. **2**, (2011).

14 Qiao, M. et al. Thiol Oxidative Stress Induced by Metabolic Disorders Amplifies Macrophage Chemotactic Responses and Accelerates Atherogenesis and Kidney Injury in LDL Receptor-Deficient Mice. *Arteriosclerosis Thrombosis Vascular Biology*. **29** 1779-1786, (2009).

15 Ullevig, S. et al. NADPH Oxidase 4 Mediates Monocyte Priming and Accelerated Chemotaxis Induced by Metabolic Stress. *Arteriosclerosis Thrombosis Vascular Biology*. **32** (2), 415-426, (2012).

16 Kim, H. S., Ullevig, S. L., Zamora, D., Lee, C. F., Asmis, R. Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment. *Proceedings of the National Academy of Science U. S. A.* **109** (41), E2803-E2812, (2012).

17 Kim, H. S., Tavakoli, S., Piefer, L. A., Nguyen, H. N., Asmis, R. Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis. *Scientific Reports*. **6** 34223, (2016).

18 Ponce, M. L. Tube formation: an in vitro matrigel angiogenesis assay. *Methods in*

485 *Molecular Biology*. **467** 183-188, (2009).

486 19 Auerbach, R., Lewis, R., Shinnars, B., Kubai, L., Akhtar, N. Angiogenesis assays: a critical
 487 overview. *Clinical Chemistry*. **49** (1), 32-40, (2003).

488 20 Kim, H. S., Ullevig, S. L., Nguyen, H. N., Vanegas, D., Asmis, R. Redox regulation of 14-3-
 489 3zeta controls monocyte migration. *Arteriosclerosis, Thrombosis, and Vascular Biology*. **34** (7),
 490 1514-1521, (2014).

491 21 Short, J. D., Downs, K., Tavakoli, S., Asmis, R. Protein Thiol Redox Signaling in Monocytes
 492 and Macrophages. *Antioxidants and Redox Signaling*. **25** (15), 816-835, (2016).

493 22 Tavakoli, S., Asmis, R. Reactive oxygen species and thiol redox signaling in the macrophage
 494 biology of atherosclerosis. *Antioxidants and Redox Signaling*. **17** (12), 1785-1795, (2012).

495 23 Ullevig, S. L. et al. Protein S-Glutathionylation Mediates Macrophage Responses to
 496 Metabolic Cues from the Extracellular Environment. *Antioxidants and Redox Signaling*. **25** (15),
 497 836-851, (2016).

498



Figure 1**A****B**



Figure 2

Figure 3

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
10 cm petri dish	griner bio-one	664 160	
10x suspension buffer	proteinsimple	R101	
15 cm petri dish	Falcon	353025	
2-Mercaptoethanol	MP	2194705	
5% washing buffer	BIOMEDICALS		
Antibody diluent	proteinsimple	R252	
	proteinsimple	042-203	
Bench Top Centrifuge	Beckman Coulter		Microfuge 22R Centrifuge
Bovine Serim Albumin	Sigma-Aldrich	A7906-100G	
Calcein AM	ThermoFisher	C3099	1 ml
CD11b	Novus Biologicals	NB110-89474	
CD45 (D4H7K) rabbit mAb	Cell Signal Technologies	727987S	
CD68/SR-D1 (FA-11)	Novus Biologicals	NBP2-33337SS	
Cellometer Vision	Nexcelom		
Dispase	BD	354235	100 ml
Dissecting sissor			
Donkey anti-Rabbit IgG secondary antibody [NL557]	Novus Biologicals	NL004	NL 557 conjugate
Donkey anti-Rat IgG (H+L) secondary antibody [DyLight 650]	Novus Biologicals	NBP1-75655	DyLight 650 conjugate
F4/80 (CI-A3-1)	Novus Biologicals	NB600-404SS	
Heat Block	effendorf	22331	Thermomixer
Lysis/Running buffer	proteinsimple	R200	
Matrigel Matrix (Grwoth Factor Reduced)	BD	354230	10 ml

Microarray scanner	PerkinElmer	ScanArray Gx	
Microcentrifuge tube	Fisher Scientific	05-408-129	
Microscope	ThermoFisher	Evos fl	Single cell western 26G
Milo	proteinsimple		
Needle	BD	305111	
Parafilm			
Probing chamber	proteinsimple	035-020	
Recombinant mouse	R&D	479-JE-050	
CCL2/JE/MCP-1 protein			
scWEST chip	proteinsimple	C300	Gene mate orbital shaker
Shaker	Bioexpress		
Single cell western chip canister	proteinsimple	035-118	
Slide spinner	Labnet	C1303-T	
Sodium Dodecyl Sulfate (SDS)	Fisher Scientific	BP 166-500	
Syringe	BD	309602	1 ml
Tris-Hydrochloride	Fisher Scientific	BP 153-500	
Tweezer	proteinsimple	035-020	
Water bath	ThermoFisher		

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	A novel method to assess monocyte chemotactic activity in vivo and characterize the ...
Author(s):	Yong Joo Ahn; Luxi Wang & Peter Asmus

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Reto Asmis	
Department:	Internal Medicine	
Institution:	Wake Forest School of Medicine	
Title:	Professor	
Signature:		Date: 4/26/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Responses to editors' comments are listed in the order they were raised:

1. All spelling and grammar issues were addressed.
2. All abbreviations are now addressed during first use.
3. The emails of the authors are as follows:

Yong Joo Ahn: yahn@wakehealth.edu
Luxi Wang: luxwang@wakehealth.edu
Reto Asmis: rasmis@wakehealth.edu
4. With the exception of "Matrigel" we have replaced all commercial language for the manuscript. There is no simple way of describing and referring to a "Matrigel" plug. Since the term "Matrigel" plug is well-known in cell biology, for the purpose of clarity, we left the term "Matrigel" in the text. The term "single cell Western blot" is not a commercial term.
5. See 3. Above.
6. The Short Abstract has been rephrased.
7. The text was reformatted as requested.
8. Lines 70-75 were reworded.
9. All text in the protocol is now written in the imperative tense, directing the reader to do something.
10. See # 9
11. The long paragraph has been split into two discrete steps.
12. More detail has been added.
13. 5 ml. This information was added.
14. We monitor respiratory rate (rate/min) and corneal reflex and movement of whiskers.
We do not use eye ointment because the injection time is less than a minute.
We spray 70% ethanol around procedure area during the procedure.
This information was added to the protocol.
15. We routinely harvested Matrigel plugs 3 days after Matrigel injection. This information was added to the protocol. For the purpose of this study, we also harvested Matrigel plugs after one and after 5 days.
16. We used primary antibodies directed against CD45, CD11b, and F4/80 in this protocol as listed in the material table. This information was added to the protocol.
17. The appropriate sections are highlighted in yellow
18. Yes, for Matrigel injections.
19. The statistics used for the analysis of the data shown in this manuscript are now described at the end of the results section.

20. All figures are original figures. No permission for reproduction is required.
21. Critical steps and troubleshooting of the techniques as well as the techniques significance and future applications are already described in the discussion. We now added a section specifically dedicated to its limitations.
22. Funding source have now been added to the Acknowledgement section.
23. Journal titles in the references have now been expanded.
24. All panels of one figure have now been combined in a single figure and were uploaded as tif files (300 dpi).

Responses to Reviewers' Comments

We thank all the reviewers for the complimentary comments and their helpful suggestions. All comments have been addressed and the necessary changes were made to the manuscript. Below please find our responses to each of the comments:

Reviewer 1:

“The innovation is moderate.” The reviewer is correct in that Matrigel-based assays have been used before, but the classic Matrigel assay was originally developed to assess angiogenesis. We believe that we are the first to use this version of the assay to assess chemokine-induced monocyte chemotaxis *in vivo*.

Reviewer 2:

“.. likely mean steatohepatitis instead of hepatic steatosis.” Yes, we do. We made the requested corrections.

... “some protocol steps highlighted in yellow, ...” The journal requires all sections to be shown in the video to be highlighted in yellow.

“... always capitalize Petri.” We made the requested corrections.

“Please provide the dilution factors.” All primary antibodies were used at a 1:20 dilution as indicated in the protocol.

“... a brief description of the statistics.” The statistical approaches used are now described at the end of the result section.

”Some sentences need revision.” We made the requested corrections.

Reviewer 3:

Major concerns:

1. **“.. the recruitment of immune cells in the Matrigel plug with MCP-1 is not higher... .”** We conducted additional experiments and updated figures 1A and 1B. At all three time points, Matrigel plug loaded with MCP-1 contained statistically significant more cells than vehicle-loaded cells, but on Day 3, the difference was maximal. Our data now show that the recruitment of cells, particularly on Day 3, is MCP-1-driven.
2. **“Poor statistical tests...”** We added a section on the statistics used throughout this manuscript at the end of the Results section. Statistics for Figure 1 were updated.
3. **... but again the difference is not statistically different...”**. We added additional experiments and updated the statistics for figure1. The differences are now statistically significant.
4. **“The authors show SEM instead of SD...”** The reviewer is correct; we now report all errors as S.D..

Minor concerns:

1. **“Include directions for the Matrigel injection to be successful. ...”** Additional directions were added to ensure the Matrigel injections are successful.

“Is formation of bubbles for example a problem?” Yes. We now added the following instructions under 1.6: “Remove all air bubbles from the Matrigel-loaded syringe before making the injection to ensure a uniform plug forms.”

“Does it need to be exactly 100ul/ sec (sounds pretty quickly) or can one do slower?” Yes, it can be injected slower. As we indicated in the protocol under 2.5: “... slowly inject (**approximately** 100 ul/ sec)...”. : “The Matrigel plugs can become irregularly shaped or even fragmented if the injection is too slow, and difficult to remove”..

2. **“ ... The kinetics between this method and the other paper’s method is different. Please explain.”** The method in the paper referenced by the reviewer is an *in vitro* method conducted in transwells, whereas our method measures monocyte recruitment *in vivo*. Furthermore, these authors used thioglycollate-elicited, i.e. highly activated peritoneal macrophages (not monocytes or monocyte-derived macrophages) for their assay. These differences alone could explain the different kinetics.
3. **“Why choose Western blot instead of flow cytometry...”** The number of cell isolated from our Matrigel plugs is too low to conduct meaningful flow cytometry experiments. Single cell Western blotting only requires 5,000 – 20,000 cells, allows for multiplexing and for stripping /re-probing of gels.
4. **“What are the leukocytes that are attracted?”** Our focus was solely on monocyte and macrophage recruitment. We therefore did not further analyze the non-monocyte/macrophage fractions.